News from Atom Therapeutics
12 November, 2024
PRESS RELEASE
Atom Therapeutics to Present Positive Data from a Phase 1 Trial of Its Novel URAT1 Inhibitor...
12 November, 2024
PRESS RELEASE
Atom Bioscience Changes Name to Atom Therapeutics To Better Reflect Focus on Development...
21 May, 2024
PRESS RELEASE
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the...
24 April, 2024
PRESS RELEASE
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial...
21 April, 2024
PRESS RELEASE
Atom Bioscience Names Hu Xianjun Clinical VP in China
JIANGSU, China (April 18, 2024)...
02 January, 2024
PRESS RELEASE
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout
JIANGSU,...
16 October, 2023
PRESS RELEASE
Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials...
09 October, 2023
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
PRESS RELEASE
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for...
22 May, 2023
PRESS RELEASE
Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating...
03 April, 2023
PRESS RELEASE
Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific...